← Leaderboards
Andrii Monastyrskyi
H. Lee Moffitt Cancer Ctr & Res Inst
$1,496,168
Attributed
$4,054,081
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $975.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,054,081 · 3
By mechanism
R01$3,519,313 · 1
R21$423,408 · 1
F32$111,360 · 1
Top collaborators
- Derek Ronald Duckett8 shared
- Eric B. Haura8 shared
- Uwe Rix2 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Eric B. Haura$11,744,471
- Derek Ronald Duckett$9,922,620
- Gina Marie Denicola$5,417,604
- John L. Cleveland$27,832,236
- Elsa R Flores$12,484,914
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsSmall MoleculePharmaceutical PreparationsMalignant NeoplasmsInsightChemotherapyApoptosisBiochemicalCancer PatientLeadAnalogStructureMalignant Breast NeoplasmMalignant Neoplasm Of LungResistanceResponseInnovationNovel TherapeuticsMissionFutureNeoplastic CellErbb2 GeneNon-Small-Cell Lung Carcinoma
Grant awards (12)
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$681,912
R01 · FY2025 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$649,046
R01 · FY2024 · CA
Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets$187,087
R21 · FY2024 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$666,289
R01 · FY2023 · CA
Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets$236,321
R21 · FY2023 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$72,662
R01 · FY2023 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$666,846
R01 · FY2022 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$74,145
R01 · FY2022 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$29,208
R01 · FY2022 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$679,205
R01 · FY2021 · CA
Development of Casein Kinase 1d and 1e Inhibitors for Treatment of Brain Cancer$57,066
F32 · FY2017 · CA · contact PI
Development of Casein Kinase 1d and 1e Inhibitors for Treatment of Brain Cancer$54,294
F32 · FY2016 · CA · contact PI